Document:

QuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 4.4  

 
 

LOCK-UP AGREEMENT    
    

                        ,
2004 

Gilford
Securities Incorporated

850 Third Avenue, 14th Floor

New York, NY 10022

Attn: Managing Director of Corporate Finance 

Gentlemen:

        The
undersigned (the "Securityholder") understands that Gilford Securities Incorporated (the
"Underwriter") has entered into a letter of intent (the "Letter of Intent") with JED Oil Inc.
(the "Company"), pursuant to which the Underwriter confirmed its intent to act as the managing underwriter in connection with a proposed public offering
(the "Offering") of shares of common stock ("Common Stock") to be issued by the Company. 

        1.     In
consideration for the Underwriter entering into the Letter of Intent and agreeing to incur expenses thereunder, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Securityholder agrees that the Securityholder will not, without the prior written consent of the Underwriter, directly or indirectly
offer, sell, pledge, contract to sell (including any short sale), grant any option to purchase, enter into any contract to sell or otherwise dispose of or transfer any shares of Common Stock to be
received by the Securityholder upon conversion of the Securityholder's options to purchase Common Stock of the Company, or enter into any Hedging Transaction (as defined below) (each of the foregoing
referred to as a "Disposition") for a period beginning on closing date (the "Closing Date") of the
Offering and continuing through and including the date that is 12 months from the Closing Date (the "Lock-Up Period"). The foregoing
restrictions are expressly intended to preclude the Securityholder from engaging in any Hedging Transaction or other transaction which is designed to or is reasonably expected to lead to or result in
a Disposition during the Lock-Up Period even if the securities would be disposed of by someone other than the Securityholder. "Hedging Transaction" means any short sale (whether or not
against the box) or any purchase, sale or grant of any right (including, without limitation, any put or call option) with respect to any security (other than a broad-based market basket or
index) that includes, relates to or derives any significant part of its value from the Common Stock. 

        2.     Notwithstanding
the foregoing, the Securityholder may transfer any or all of the Securityholder's Common Stock: (i) if the Securityholder is a natural person, by
gift, will or intestacy so long as the transfer is not for value; (ii) if the Securityholder is a natural person, to any trust for the direct or indirect benefit of the Securityholder or the
immediate family of the Securityholder so long as the transfer is not for value; (iii) if the Securityholder is a partnership, to a partner of such partnership or a retired partner of such
partnership who retires after the date hereof so long as the transfer is not for value; and (iv) if the Securityholder is a corporation, limited liability company or limited partnership to any
of its wholly-owned subsidiaries; provided, however, that in any such case it shall be a condition to the transfer that, prior to or concurrently with such transfer, the transferee executes and
delivers to the Underwriter an agreement, in form and substance satisfactory to the Underwriter, stating that the transferee is receiving and agrees to hold the Common Stock, as the case may be,
subject to the provisions of this Lock-Up Agreement, and there shall be no further transfer of such Common Stock, as the case may be, except in accordance with this Lock-Up
Agreement. For purposes of this Lock-Up Agreement, "immediate family" shall mean any relationship by blood, marriage, or adoption, not more remote than first cousin. 

        3.     Without
limiting the restrictions herein, any Disposition by the Securityholder shall remain at all times subject to applicable securities laws, including without
limitation the resale restrictions imposed by Rule 144 promulgated under the Securities Act of 1933, as amended. 

 

        4.     The
Securityholder hereby agrees that, to the extent the terms of this Lock-Up Agreement conflict with or are in any way inconsistent with any registration
rights agreement or similar agreement to which the Securityholder is a party or under which the Securityholder is entitled to any right or benefit, this Lock-Up Agreement supersedes such
registration rights agreement or similar agreement. 

        5.     The
Securityholder understands that the Company and the Underwriter intend to proceed with the Offering in reliance on this Lock-Up Agreement. 

        6.     This
Lock-Up Agreement shall immediately terminate, and the Securityholder shall have no further obligations, nor shall the Underwriter have any further
rights, under this Lock-Up Agreement, if the Letter of Intent is terminated at any time. 

        7.     This
Agreement shall be governed by and construed in accordance with the internal laws of the State of New York without regard to the conflicts of laws principles
thereof. The parties hereto hereby irrevocably agree that any suit or proceeding arising directly or indirectly pursuant to or under this Lock-Up Agreement, shall be brought solely in a
federal or state court located in the City, County and State of New York. By its execution hereof, the parties hereby covenant and irrevocably submit to the in
personam jurisdiction of the federal and state courts located in the City, County and State of New York and agree that any process in any such action may be served upon any of
them personally, or by certified mail or registered mail upon them or their agent, return receipt requested, with the same full force and effect as if personally served upon them in New York City. The
parties hereto waive any claim that any such jurisdiction is not a convenient forum for any such suit or proceeding and any defense or lack of in
personam jurisdiction with respect thereto. In the event of any such action or proceeding, the party prevailing therein shall be entitled to payment from the other party hereto
of its reasonable counsel fees and disbursements. 

        8.     The
Securityholder hereby represents and warrants that the Securityholder has full power and authority to enter into this Lock-Up Agreement and that this
Lock-Up Agreement has been duly authorized (if applicable), executed and delivered by the Securityholder and is a valid and binding agreement of the Securityholder. All authority herein
conferred or agreed to be conferred shall survive the death or incapacity of the Securityholder and any obligations of the Securityholder shall be binding upon the heirs, personal representatives,
successors and assigns of the Securityholder. 

	Very truly yours,	 	 
	

 (Signature)	
 	

 
	

 (Print Name)	
 	

 

2

QuickLinks

LOCK-UP AGREEMENTExhibit 10.20  

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED AS "(CONFIDENTIAL TREATMENT REQUESTED)" IN THE TEXT, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

AMIFOSTINE MANUFACTURING AND SUPPLY AGREEMENT 

        This
Agreement ("Agreement"), entered into as of the 1st day of January, 2001 (the "Effective Date"), by and between MedImmune Oncology, Inc. (formerly U.S.
Bioscience, Inc., hereinafter referred to as "MedImmune Oncology"), a corporation duly formed and existing under the laws of the State of Delaware, having a place of business at One Tower
Bridge, 100 Front Street, West Conshohocken, Pennsylvania 19428, and PPG Industries, Inc., having a place of business as One PPG Place, Pittsburgh, Pennsylvania 15272, USA, and its wholly-owned
subsidiary PPG-Sipsy, having a place of business at Z.I. la Croix Cadeau, B.P. 79, 49242 Avrille Cedex, France (Individually & Collectively "PPG"), a corporation duly
formed and existing under the laws of the State of Pennsylvania. 

WITNESSETH 

        WHEREAS,
the parties to this Agreement are parties to a Manufacturing and Supply Agreement between U.S. Bioscience, Inc. and Sipsy, S.A. (the "Prior Agreement") relating to the
manufacture of amifostine; 

        WHEREAS,
MedImmune Oncology has certain proprietary technical information (including, without limitation, patents, patent applications and trade secrets) relating to the Product which
has been disclosed, in part, to PPG under the terms of the Prior Agreement and which will be disclosed, in part, to PPG under the terms of this Agreement; 

        WHEREAS,
the parties desire to have this Agreement supersede the Prior Agreement from and after the Effective Date; 

        WHEREAS,
MedImmune Oncology desires to contract with PPG for the continued manufacture of amifostine (hereinafter defined in Section 1.4 and referred to as the "Product"); and 

        WHEREAS,
PPG desires to manufacture the Product for MedImmune Oncology and represents that it possesses the requisite expertise, personnel and facilities for the manufacture and supply
of Product on the terms and in the quantities contemplated by this Agreement. 

        NOW
THEREFORE, in consideration of the foregoing and of the mutual covenants and conditions herein contained, the parties hereby agree as follows: 

ARTICLE I 

DEFINITIONS

        For
purpose of this Agreement: 

        Section 1.1  "cGMPs"
shall mean the current Good Manufacturing Practices promulgated by the United States Food and Drug Administration ("FDA") and other applicable
government regulatory agencies. MedImmune Oncology shall keep PPG regularly informed about any amendment or modification to relevant portions of its regulatory registrations for the Product. 

        Section 1.2  "Confidential
Information" shall have the meaning set forth in Section 7.1. 

1

 

        Section 1.3  "Preparation"
and/or "Prepare" shall mean any and all steps and operations required in the sourcing of raw material, synthesis, manufacture, processing,
subdividing, quality control, quality assurance, testing, storage and packaging of Product for shipment. 

        Section 1.4  "Product"
shall mean Amifostine Drug Substance together with changes, modifications and improvements instituted during the term hereof as described more
fully on Exhibit "C" attached and made a part hereof. 

        Section 1.5  "Specifications"
shall have the meaning set forth in Section 4.1 hereof. 

        Section 1.6  "Contract
Year" shall mean a calendar year under this Agreement. 

ARTICLE II 

SALE
AND DELIVERY OF PRODUCT 

        Section 2.1  Subject
to the terms and conditions set forth in this Agreement, PPG agrees to Prepare and sell, and MedImmune Oncology agrees to purchase from PPG, the
Product as follows: 

Prior
to the beginning of each calendar quarter, MedImmune Oncology shall provide to PPG, in writing, a (CONFIDENTIAL TREATMENT REQUESTED) forecast of its requirements for deliveries of the Product
during the next (CONFIDENTIAL TREATMENT REQUESTED) (hereinafter the "Delivery Schedule"). The quantities forecast for delivery in the (CONFIDENTIAL TREATMENT REQUESTED) in a Delivery Schedule shall be
firm commitments to purchase and sell; and the (CONFIDENTIAL TREATMENT REQUESTED) included in a Delivery Schedule shall be for planning purposes and may be revised up or down by MedImmune Oncology.
Exhibit "A" sets forth MedImmune Oncology's non-binding requirements forecast for the Contract Years 2001-2003. 

        Section 2.2  PPG
agrees, at the request of MedImmune Oncology, to provide Product at the agreed upon price set forth in the Price Schedule attached hereto as
Exhibit "B" and subject to the provisions of Section 3.1. 

        Section 2.3  Subject
to Section 2.5, PPG shall provide (CONFIDENTIAL TREATMENT REQUESTED) to (CONFIDENTIAL TREATMENT REQUESTED) of MedImmune Oncology's
requirements for the Product, at MedImmune Oncology's option. Subject to Section 2.5, MedImmune Oncology shall purchase from PPG a minimum of (CONFIDENTIAL TREATMENT REQUESTED) to (CONFIDENTIAL
TREATMENT REQUESTED) of MedImmune Oncology's global requirements for the Product, provided however, that PPG may elect to qualify a second manufacturing location for production of Product by informing
of its intent to do so in writing. Within 90 days of such notification, PPG will provide to MedImmune documentation which describes PPG's qualification protocols and
validation plans. PPG and MedImmune will cooperate to complete such qualification in a timely manner. Upon successful qualification of the alternate manufacturing location by MedImmune, MedImmune
shall be obligated to purchase (CONFIDENTIAL TREATMENT REQUESTED) of MedImmune Oncology's global requirement for Product. 

        Section 2.4  PPG
shall at all times maintain a minimum inventory of at least (CONFIDENTIAL TREATMENT REQUESTED) of the amount of the Product purchased by MedImmune
Oncology during the preceding (CONFIDENTIAL TREATMENT REQUESTED). PPG shall at all times maintain a minimum annual capacity reserved for production of the Product for MedImmune Oncology of the
quantity of Product specified for delivery in the most recent Delivery Schedule. Notwithstanding anything to the contrary in this Section 2.3, should PPG be required to replace Product pursuant
to its obligations in Article 4, PPG may utilize the inventory of the Product even though that may result in a temporary situation in which inventory is less than required by this
Section 2.4. PPG shall rebuild the 

2

 

inventory
to once again meet the requirements of this Section 2.4 within (CONFIDENTIAL TREATMENT REQUESTED) days of removing Product to use as replacement Product. 

        Section 2.5  If
PPG has not qualified an alternative manufacturing site subject to Section 2.3, MedImmune Oncology may qualify an alternative source(s) of
supply other than PPG and may secure Product from such alternative source(s) for amounts in excess of (CONFIDENTIAL TREATMENT REQUESTED) of its requirements. MedImmune Oncology shall not make the
alternative source(s) MedImmune Oncology's principal supplier of Product unless PPG has materially failed to meet MedImmune Oncology's orders in a period of more than (CONFIDENTIAL TREATMENT
REQUESTED) or this Agreement is terminated or has by its terms expired. After (CONFIDENTIAL TREATMENT REQUESTED) in which PPG has materially failed to meet MedImmune Oncology's orders, both parties
agree that MedImmune Oncology may use an alternate source to supply MedImmune Oncology's needs until PPG is able to again furnish MedImmune Oncology's needs. 

        Section 2.6  PPG
agrees to sell the Product exclusively to MedImmune for pharmaceutical applications. PPG agrees that during the term of this Agreement and for a
period of (CONFIDENTIAL TREATMENT REQUESTED) thereafter, it will not compete, or assist third parties to compete, directly or indirectly with MedImmune Oncology in the sale of the Product. 

        Section 2.7  MedImmune
Oncology shall submit purchase orders for Product to PPG at least (CONFIDENTIAL TREATMENT REQUESTED) prior to the date of shipment specified
therein. MedImmune Oncology's purchase orders shall (i) reference this Agreement; (ii) be submitted in writing; (iii) state the quantity of Product ordered; (iv) specify
the delivery location; and (v) state the desired date of shipment. In no event shall the use of any form of purchase order be effective to vary, alter, modify or add to the terms and provisions
of this Agreement; nor will the acceptance of any such purchase order have the effect of substituting the provisions set forth on such form for the provisions contained in this Agreement. MedImmune
Oncology may reschedule such purchase order no later than (CONFIDENTIAL TREATMENT REQUESTED) prior to the date of scheduled manufacturing. In no
event shall MedImmune Oncology's right to reschedule such Purchase Order abrogate any of its obligations under Section 2.1. 

        Section 2.8  PPG
shall exercise reasonable, diligent efforts to ship Product in the quantities and on the dates specified in MedImmune Oncology's purchase orders.
Sales of Product by PPG to MedImmune Oncology shall be made CIP (as in Incoterms 1990), to MedImmune Oncology's facility in Nijmegen, the Netherlands, or such other location as may be specified by
MedImmune Oncology to PPG from time to time hereunder. 

ARTICLE III 

PAYMENT
TERMS 

        Section 3.1  The
Base Prices to be paid by MedImmune Oncology for quantities of Product purchased pursuant to this Agreement are set forth in Exhibit "B",
except for freight and insurance which will be billed (CONFIDENTIAL TREATMENT REQUESTED). The prices set forth on Exhibit "B" shall be subject to the following adjustments, as applicable: 

        PPG
and MedImmune Oncology will adjust the prices in Exhibit B such that any benefit or loss due to the change in exchange rate will be shared equally by the parties according to
the following: 

Average
Exchange Rate ("AER") is defined as the average Euro per US$ exchange rate which has prevailed for the previous (CONFIDENTIAL TREATMENT REQUESTED) prior to the date of invoicing. 

3

 

"Invoice
Price" is defined as such: 

For
invoices for which the AER is greater than or equal to (CONFIDENTIAL TREATMENT REQUESTED) Euro per US$ and less than or equal to (CONFIDENTIAL TREATMENT REQUESTED) per US$ the Invoice Price is
equal to (CONFIDENTIAL TREATMENT REQUESTED) divided by the AER multiplied by the Base Price then in effect 

For
invoices for which the AER is greater than (CONFIDENTIAL TREATMENT REQUESTED) the Invoice Price is equal to (CONFIDENTIAL TREATMENT REQUESTED) multiplied by the Base Price then in effect. 

For
invoices for which the AER is less than (CONFIDENTIAL TREATMENT REQUESTED) the Invoice Price is equal to (CONFIDENTIAL TREATMENT REQUESTED) multiplied by the Base Price then in effect. 

In
summary: 

For
AER>(CONFIDENTIAL TREATMENT REQUESTED) Invoice price = (CONFIDENTIAL TREATMENT REQUESTED)× Base Price in effect 

For
(CONFIDENTIAL TREATMENT REQUESTED)<AER<(CONFIDENTIAL TREATMENT REQUESTED) Invoice price= (CONFIDENTIAL TREATMENT
REQUESTED)/AER × Base Price in effect 

For
AER<(CONFIDENTIAL TREATMENT REQUESTED) Invoice price = (CONFIDENTIAL TREATMENT REQUESTED) × Base Price in effect 

        In
the event that MedImmune Oncology makes changes to the Specifications which result in material increases in the cost to PPG to Prepare the Product, PPG and MedImmune Oncology shall
negotiate in good faith an appropriate and reasonable price adjustment. In the event that the regulatory authorities other than the regulatory authorities of the United States, the EC countries or
Japan, require additional cGMP requirements or changes to the Specifications in order to allow commercialization of Product in their respective countries, the parties shall negotiate in good faith an
appropriate and reasonable price adjustment relating solely to quantities of Product for which such changes are necessary. 

        In
the event that the parties do not agree on such price adjustment, then both parties will appoint a mutually acceptable independent expert whose findings will be binding on both PPG
and MedImmune Oncology. Said expert shall transmit to both parties its findings within three months from the date of its appointment. If the parties are unable to agree on an independent expert, the
matter shall be settled in accordance with Section 12.3 hereof. 

        Section 3.2  All
prices of Product shall be on the basis of (CONFIDENTIAL TREATMENT REQUESTED) as in Incoterms 1990. 

        Section 3.3  The
purchase price for Product shall be paid to PPG no later than (CONFIDENTIAL TREATMENT REQUESTED) days after the date of PPG's invoice to MedImmune
Oncology. In no event shall PPG invoice MedImmune Oncology for the Product prior to delivery. All invoices from PPG to MedImmune Oncology covering Product shipped to MedImmune Oncology shall be stated
in, and all payments to PPG by MedImmune Oncology shall be made in United States Dollars (US$). However, the parties hereto may agree at the beginning of each Contract Year that such invoices and
payments will be in European Monetary Units (Euro), provided, however, that said prices may be adjusted by mutual agreement of the parties by an amount sufficient to cover PPG'S currency exchange risk
and costs. 

        In
the event that the Euro to US$ exchange rate is greater than (CONFIDENTIAL TREATMENT REQUESTED) or less than (CONFIDENTIAL TREATMENT REQUESTED) for 

4

 

more
than (CONFIDENTIAL TREATMENT REQUESTED), then either party may request a renegotiation of the Base Prices in Exhibit "B" in writing to the other party. Both parties will commence such
negotiations within 30 days of receipt of the written request. If the parties fail to agree to a modification of the base prices within 60 days of commencement of the negotiation, then
the dispute will be settled in accordance with Section 12.3. 

        Section 3.4  Payments
due to PPG shall be made by wire transfer or by a mutually agreeable method to the bank account of PPG of which PPG shall advise MedImmune
Oncology from time to time. 

ARTICLE IV 

MANUFACTURE
AND SUPPLY 

        Section 4.1  Prior
to the date of the Prior Agreement, MedImmune Oncology (then U.S. Bioscience, Inc.) transferred to PPG, and PPG hereby acknowledges receipt
of, copies of MedImmune Oncology's specifications for the manufacture and testing of the Product, and such specifications have been revised from time to time under the Prior Agreement. The current
specifications for the Product are attached hereto as Exhibit "C" and made a part hereof (such specifications, as revised in accordance with this Section 4.1, hereinafter being defined
as the "Specifications"). The Preparation of the Product shall be carried out by PPG in accordance with applicable cGMPs and established quality standards. The Product shall meet Specifications.
MedImmune Oncology shall provide PPG with all revisions to the Specifications in a timely manner after such revisions are approved by MedImmune Oncology, as
appropriate, such revisions to be reasonably required for the Product. All revisions or deviations from Specifications for Product must be made in accordance with the Change Control Procedures set
forth in Exhibit "D". 

        Section 4.2  PPG
shall prepare and make available to MedImmune Oncology for review and comment comprehensive and complete documentation including the Drug Master
File(s) with regard to the manufacture and testing of Product which will include, but not be limited to, testing of all raw materials, in-process and finished product applications; and
review of master and working batch records for processing and packaging and all supporting analytical documentation. Such documentation shall be in a format consistent with cGMP's or FDA or other
regulatory agencies requirements, and shall be prepared with respect to the manufacture of each batch of Product. 

        Section 4.3  PPG
shall prepare and maintain a current master production batch record in English. At the time of execution of this Agreement, PPG shall provide
MedImmune Oncology with a copy of the then current master production batch record in English. Thereafter, PPG shall provide to MedImmune Oncology any updates of this master record in English within
(CONFIDENTIAL TREATMENT REQUESTED) of any such update being submitted. PPG shall not change the master production batch record without the prior written approval of MedImmune Oncology. 

        Section 4.4  For
each batch Prepared, PPG shall provide MedImmune Oncology with a certificate of analysis and a certificate of compliance, specifically providing that
the Product meets Specifications, in the English language, for the Product no later than (CONFIDENTIAL TREATMENT REQUESTED) after completion of manufacture of such batch. 

        Section 4.5  Within
(CONFIDENTIAL TREATMENT REQUESTED) from receipt by MedImmune Oncology of the certificate of analysis for Product set forth in Section 4.4,
MedImmune Oncology shall notify PPG in writing whether it approves of the release of Product for shipment. Upon receipt of such notification from MedImmune Oncology, PPG shall within one
(1) week ship the certificated amount of Product to MedImmune Oncology's designee. 

        MedImmune
Oncology shall confirm to PPG in writing within (CONFIDENTIAL TREATMENT REQUESTED) of arrival of a shipment of Product, the identity and amount of Product received, and 

5

 

condition
of the shipment based solely upon a visual inspection. Such MedImmune Oncology confirmation shall not constitute acceptance of the Product, nor shall it be construed as any indication of
whether or not the Product conforms to Specifications. 

        Section 4.6  MedImmune
Oncology or its designee shall have (CONFIDENTIAL TREATMENT REQUESTED) after shipment to inspect each shipment of Product to determine whether
the Product included in such shipment conforms to the Specifications. MedImmune Oncology shall promptly give PPG written notice of any aspect in which Product fails to conform to Specifications. If
MedImmune Oncology fails to notify PPG of any nonconformity within such (CONFIDENTIAL TREATMENT REQUESTED) period, MedImmune Oncology shall be deemed to have accepted the Product as shipped, provided,
however, that with respect to any nonconformity due to latent defects, MedImmune Oncology shall be entitled to reject the nonconforming Product within (CONFIDENTIAL TREATMENT REQUESTED) after
discovering the latent defects. In the event of contestation of quality by MedImmune Oncology as provided in this Section and that such contestation is not accepted by PPG, a sample of the contested
batch sealed by PPG in compliance with applicable regulations shall be submitted by PPG to a relevant state approved unrelated and independent laboratory, mutually acceptable to both parties, and the
check assay of said laboratory shall be accepted by the two parties as final and binding. The cost of said analysis made by the laboratory shall be borne by the failing party. 

        If
any production batches of the Product fail to meet the Specifications as evidenced by the laboratory check assay, MedImmune Oncology shall have the right to return such batches, in
which case the cost of the rejected batches (including raw materials, labor, manufacturing overhead and quality control) or, if applicable, the cost of any work (any rework not included in the Drug
Manufacturing File must be approved in advance by MedImmune Oncology) will be borne by PPG unless such failure is due to the negligence of MedImmune Oncology. In the event that MedImmune Oncology
rejects or returns any batch of Product pursuant to this Section, it shall receive replacement of such batch. In no event shall MedImmune Oncology's damages for rejected Product batches exceed
(CONFIDENTIAL TREATMENT REQUESTED). 

        Section 4.7  PPG
shall make its best reasonable efforts to replace Product as quickly as possible but in no case more than (CONFIDENTIAL TREATMENT REQUESTED) after
notification of MedImmune Oncology of nonconformity pursuant to Section 4.6. 

        Section 4.8  In
the event the check assay made by the laboratory as provided in Section 4.6 hereabove concludes the nonconformity of the Product, MedImmune
Oncology and PPG shall meet immediately to agree upon the corrective actions, if any, to be implemented. PPG will cease further production of the Product until MedImmune Oncology and PPG formally
agree in writing on such corrective actions. PPG may at its own risk continue to produce Product during this period with no obligation to MedImmune Oncology. Should MedImmune Oncology desire to have
Product produced while the investigation is in process, MedImmune Oncology will be responsible for the fees for service of PPG whether the batch is accepted or not. Should PPG be required by MedImmune
Oncology to produce any experimental batches of Product to elucidate or resolve the source of the batch rejection, billings for these batches will be separate from and exclusive of the fees stated in
the attachment. 

        Section 4.9  PPG
shall provide access to information and support needed during investigations addressing customer complaints and/or recalls. All documents and updates
with regard to the Preparation of the Product which are required by any regulatory agency shall be provided by PPG, and PPG shall submit to all inquiries and inspections by such regulatory agencies.
All documents provided by PPG to any regulatory agency shall be provided to MedImmune Oncology in advance, if feasible, and in no case shall such documents be provided to MedImmune Oncology more than
two (2) days after such documents are provided to any regulatory agency. 

6

 

        Section 4.10  PPG
shall properly dispose of all manufacturing waste and associated contaminated materials in accordance with all applicable laws, including French laws
and environmental regulations. Upon MedImmune Oncology's request, PPG shall supply to the FDA or any official government agency an official statement, a model of which is attached hereto as
Exhibit "E" stating that PPG is in conformance with relevant environmental regulations. PPG shall provide at the request of MedImmune Oncology from time to time a letter from the appropriate
governmental authority certifying that the site is in compliance with environmental laws applicable to PPG. 

        Section 4.11  PPG
shall maintain its facilities utilized in the performance of this Agreement or which in any way affect such performance to meet all cGMP
requirements. 

ARTICLE V 

STORAGE 

        Section 5.1  PPG
shall purchase, receive, test, store and secure all Product and materials used for the Preparation of the Product by means which meet all cGMP
requirements. 

ARTICLE VI 

QUALITY
CONTROL 

        Section 6.1  PPG
shall perform quality control and quality assurance review of all aspects of Product Preparation on an individual batch basis. Such review shall
include, but shall not be limited to: raw material handling and testing, manufacturing, including all reprocessing and packaging,
in-process and finished product testing. The review shall be made to ensure and certify compliance of all PPG's activities to all Specifications and cGMP requirements for the Product. Such
quality control and quality assurance review shall include acceptance and approval of all associated documentation, as more fully set forth in Sections 4.2, 4.3, and 4.4 by PPG on an individual
batch basis. 

        Section 6.2  PPG
shall keep all samples including raw materials, in process and final Product relating to the manufacture of each batch of the Product in accordance
with the cGMP provided said samples do not represent a danger and are in stable substance form. 

        In
the event of an investigation or claim from a third party made to MedImmune Oncology, PPG shall, except as provided hereabove, provide MedImmune Oncology on MedImmune Oncology's
request, a sample of raw materials, in-process samples and/or final Product from a production batch of the Product only. 

        Upon
MedImmune Oncology's request, PPG shall supply to MedImmune Oncology an official statement stating that drug substance reserve samples of Product are kept in compliance with cGMP,
except as provided hereabove. 

        Section 6.3  PPG
shall promptly notify MedImmune Oncology of any FDA or other regulatory agency inspections, pre-approval inspections, or any other FDA or
other regulatory interactions relating to PPG operations and concerning the manufacture of the Product. 

        PPG
shall provide MedImmune Oncology with copies of all regulatory inspections and reports, including reports of the FDA, within 48 hours of receipt of such reports by PPG. 

        Section 6.4  Nothing
contained in this Article VI shall relieve PPG of its responsibility to Prepare the Product in accordance with the Specifications and to
perform the necessary quality control tests and quality assurance review on the Product. 

7

 

ARTICLE VII 

CONFIDENTIALITY—PATENT
RIGHTS 

        Section 7.1  MedImmune
Oncology and PPG agree that all data disclosed to the other party pursuant to the Prior Agreement or this Agreement or otherwise related to the
Preparation or distribution of the Product, except as stated below, is of a most highly confidential nature (the "Confidential Information"), and in accepting such data for its internal use the
receiving party has agreed and agrees to use such Confidential Information for no other purpose than in furtherance of the transactions contemplated by this Agreement and to protect and maintain such
data in strict confidence and not disclose such data, or any part thereof, to any person, firm or other entity, including but not limited to affiliates and subsidiaries of the receiving party, except
to (i) employees of the receiving party, or its affiliates or subsidiaries who are bound by legally enforceable written agreements to keep said data confidential; (ii) any government
agency if required by law or regulation in connection with the performance of the terms of this Agreement or in support of regulatory filings; or (iii) third parties upon prior written consent
of the disclosing party. The confidentiality provisions set forth herein shall survive termination of this Agreement during a period of five (5) years regardless of the cause of termination.
The confidentiality provisions shall apply to Confidential Information except to the extent that: 

	(i)
	Information
is already or will be properly in the public domain at the time of disclosure;

	(ii)
	Information
is known to the recipient prior to communication by the disclosing party (or its predecessor) as shall be established by competent proof by the recipient;

	(iii)
	Information
which is required by law, administrative or judicial order to be disclosed, provided that such disclosure is subject to all applicable governmental or
judicial protection available for like material and the recipient notifies the disclosing party in writing in advance of such intended disclosure, promptly after the recipient becomes aware of the
disclosure requirement. 

        Section 7.2  PPG
agrees that it shall not use or assist or permit any other person or party to use any MedImmune Oncology Confidential Information, marketing data,
Preparation, distribution or business information obtained as a result of the transactions hereunder, in any way which interferes with the marketing or sales, by MedImmune Oncology or its
duly-appointed agents, employees, representatives, distributors, subsidiaries or affiliates, of the Product subject to this Agreement. 

        Section 7.3  Upon
expiration or termination of this Agreement, the receiving party shall return to the disclosing party all originals and copies of manuals,
correspondence, documents, records or other confidential written instructions it may have received concerning the Preparation of Product except that the receiving party's Legal Department may retain
one set of copies of such materials in its secured records for purposes of defining and/or meeting its obligations of confidentiality hereunder or for use as otherwise contemplated in this Agreement.
If equipment was purchased by MedImmune Oncology for projects under this Agreement, said equipment will be returned to MedImmune Oncology upon termination of this Agreement unless otherwise specified.
Notwithstanding any other provision of this Agreement and subject to Section 7.4 (iv) hereof, PPG agrees that upon expiration or termination of this Agreement, MedImmune Oncology shall
have the full unencumbered right without further payment to use PPG Confidential Information related to the Preparation of the Product to Prepare and have others on its behalf Prepare the Product. 

        Section 7.4  PPG
agrees to communicate promptly to MedImmune Oncology any ideas and improvements conceived or made by PPG after the Effective Date arising from PPG's
activities under this Agreement and relating to the processing or production of the Product (hereinafter referred to as the "Improvement") under the following conditions. 

8

 

	(i)
	All
rights and title to Improvements (patented, patentable or unpatentable) which are related to said processing or production without any other foreseeable applications
shall be assigned to MedImmune Oncology, without cost to MedImmune Oncology, which shall have the right to utilize such Improvements freely in the process of the Product;

	(ii)
	All
rights and title to Improvements (patented, patentable or unpatentable) which apply to said processing and production and which have also other applications, and
provided that specific know-how of PPG developed prior to the execution date of the Prior Agreement is not contained in said Improvements shall be licensed to MedImmune Oncology without
cost to MedImmune Oncology (subject to Section 7.4(iv)), on a perpetual, royalty-free worldwide exclusive basis, to utilize such Improvements freely in the process of the Product
only;

	(iii)
	A
perpetual, royalty-free worldwide exclusive license limited to processing or production of the Product shall be granted by PPG to MedImmune Oncology,
without cost to MedImmune Oncology (subject to Section 7.4(iv)), for Improvements (patented, patentable or unpatentable) related to said processing and which also have other application but in
which specific PPG's know-how developed prior to the execution date of the Prior Agreement is contained; and

	(iv)
	In
the event that MedImmune Oncology obtains rights pursuant to Section 7.4(ii) or (iii) to any Improvements that materially reduce the cost of the
process of the Product and MedImmune Oncology elects to qualify an alternative source(s) using these rights, then MedImmune Oncology agrees to pay a royalty to PPG for such improvements used by such
alternative source. This royalty payment will be negotiated in good faith and mutually agreeable terms and will equal (CONFIDENTIAL TREATMENT REQUESTED). PPG agrees that it will assist in the transfer
of the technology with PPG's reasonable out-of-pocket expenses paid by MedImmune Oncology. 

        Section 7.5  All
proprietary data, technology and information relating to the use, application or manufacture of Product or any improvement, modification or refinement
thereof, whether patented or unpatented, which is developed or acquired by PPG shall be treated as Confidential Information first disclosed and made known to PPG by MedImmune hereunder and shall be
maintained and administered by PPG in accordance with the provisions of Sections 7.1, 7.2, 7.3 and 7.4. PPG agrees to do and cause to be done all matters and things as it may reasonably and
lawfully be required to do to secure to MedImmune Oncology the full right of use and enjoyment thereof in and for all countries, including any and all measures necessary to insure that title to
MedImmune Oncology in and to the aforementioned inventions and other materials shall be full and clear of any claim of any of its present or future employees. PPG also agrees to cooperate with
MedImmune Oncology to the full extent necessary in the filing and prosecutions of any patent applications, including the execution of any documents required in connections herewith. 

ARTICLE VIII 

WARRANTIES
AND INSPECTION 

        Section 8.1
PPG  warrants that it will Prepare and test the Products in accordance with cGMPs and the requirements established for the Product in the Specifications. 

        Section 8.2  MedImmune
Oncology or its authorized representatives, upon reasonable notice, shall have the right, at its sole cost and expense, to conduct during normal
business hours and days quality assurance audits or other inspections of PPG's facilities to inspect and observe PPG compliance with cGMP, PPG's Preparation, quality control and quality assurance
procedures. During such audits MedImmune Oncology shall have access to facilities, equipment and documentation. 

9

   
        Section 8.3  PPG shall make available to MedImmune Oncology during quality assurance audits or other inspections all records and documentation relating to the
Preparation and quality control of Product. PPG shall also provide MedImmune Oncology, at MedImmune Oncology's reasonable request, with copies of such records during on-site inspections. 

ARTICLE IX 

FORCE
MAJEURE 

        Section 9.1
Neither party shall be liable for failure to perform or for delay in performing any provision of this Agreement that such party is required to perform, if such failure
or delay is caused by labor disputes, lack of supply of materials through no fault of such party, an act of God, riot, fire, explosion, flood, hostilities of war, executive legislation or
administrative order, restriction or controls of any governmental agency, or other conditions reasonably beyond the control of such party. However, if any such cause results in a delay in performance
of this Agreement by either party by more than sixty (60) days, then the parties shall meet and discuss what, if any, modifications of the terms of the Agreement may be required in order to
arrive at an equitable solution. 

ARTICLE X 

INDEMNIFICATION

        Section 10.1  Except
as provided in Section 10.2, MedImmune Oncology agrees to indemnify and hold PPG harmless from and against any loss, damage, liability or
expense to PPG (including without limitation reasonable attorneys fees) arising out of or in connection with (i) any action, suit, claim, demand or prosecution that may be brought or instituted
against PPG based on or arising out of MedImmune Oncology's distribution of Product, and (ii) any recalls involving Product. Notwithstanding harmless PPG to the extent that any such action,
suit, claim, demand, or prosecution arises out of PPG's failure to conform to cGMPs or other applicable regulatory standard, or out of PPG's negligence, willful misconduct, or illegal conduct. 

        Section 10.2  PPG
agrees to indemnify and hold MedImmune Oncology harmless from and against any loss, damage, liability or expense (including without limitation
reasonable attorneys fees) arising out of or in connection with any action, suit, claim, demand or prosecution that may be brought or instituted against MedImmune Oncology resulting from: 

	(i)
	Product
that materially failed to meet the Specifications at the time of shipment, unless such failure was or reasonably should have been detected by MedImmune Oncology
utilizing the testing procedures then in effect on receipt of the Product in compliance with the provisions of Section 4.6;

	(ii)
	PPG's
negligence or its failure to comply with applicable law or government regulations or cGMP with respect to PPG's responsibilities in the Preparation of Product
unless such failure was detected by MedImmune Oncology utilizing the testing procedures then in effect on receipt of the Product in compliance with the provisions of Sections 4.6; or

	(iii)
	Breach
by PPG of any covenant, representation, or warranty contained in the Agreement unless such failure was detected by MedImmune Oncology utilizing the testing
procedures then in effect on receipt of the Product in compliance with the provisions of Sections 4.6. 

        Section 10.3  If
any action, suit, claim, demand or prosecution (collectively, an "Action") is brought against a party (the "Indemnitee") in respect of indemnification
which may be sought hereunder, the Indemnitee shall immediately notify the party who is to Indemnify (the "Indemnitor") of such Action and shall extend to the Indemnitor the opportunity to defend
against such Action, at the Indemnitor's sole expense and through legal counsel reasonably acceptable to Indemnitee, provided that the 

10

 

Indemnitor
proceeds in good faith, expeditiously and diligently. Indemnitee shall, at its option and expense, have the right to participate in any defense undertaken by Indemnitor with legal counsel
of its own selection. No settlement or compromise of any action may be made by Indemnitee without the prior written consent of Indemnitor. 

ARTICLE XI 

TERM
OF AGREEMENT 

        Section 11.1  This
Agreement shall come into effect on the Effective Date as set forth at the beginning hereof and shall supersede the Prior Agreement thereafter.
Unless earlier terminated in accordance with the provisions hereof, this Agreement shall remain in force until December 31, 2005. This Agreement shall automatically be then extended for
consecutive two (2) year periods, unless either party notifies the other, in writing, of its intention not to renew at least (CONFIDENTIAL TREATMENT REQUESTED) prior to the expiration of the
initial term of this Agreement or at any time thereafter. 

        Section 11.2  Upon
early termination of this Agreement consequent to a failure by PPG, PPG will cooperate fully with MedImmune Oncology to facilitate transfer of all
manufacturing aspects, equipment, material, documentation and all other items related to the manufacture of Products to any MedImmune Oncology identified alternative manufacturing site(s). Should
MedImmune Oncology be unable to identify, qualify and receive FDA approval of any alternative manufacturing site within the (CONFIDENTIAL TREATMENT REQUESTED) notification period provided in
Section 11.1 despite all reasonable efforts and due diligence, PPG will continue to manufacture the Product for an additional (CONFIDENTIAL TREATMENT REQUESTED) grace period or until an
appropriate manufacturing site is able to produce the Product, whichever occurs first. PPG's cooperation in facilitating such transfer shall be at no cost to MedImmune Oncology. 

        Section 11.3  Notwithstanding
the cause of termination, the foregoing undertakings of confidentiality, non-use and non-competition agreed to in
this Agreement shall continue and remain in full force and effect subject to provisions of Section 2.6. 

        Section 11.4  Either
party may terminate this Agreement for a material breach by the other party by giving the breaching party written notice, specifying the breach
relied on, and giving the breaching party (CONFIDENTIAL TREATMENT REQUESTED) to cure such breach. If the default has not been cured at the end of the (CONFIDENTIAL TREATMENT REQUESTED) period, then,
upon notice thereof to the breaching party by the other, this Agreement shall terminate. 

        Section 11.5  In
the event of filing of a petition of bankruptcy or insolvency by either party or the appointment of a receiver for property of either party, the other
party may immediately terminate this Agreement with no liability whatsoever to the first party, subject however to relevant legislation. 

        Section 11.6  Any
termination of this Agreement will have no effect on performance obligations or amounts to be paid which have accrued up to the effective date of
such termination. 

ARTICLE XII 

MISCELLANEOUS

        Section 12.1  The
parties hereto undertake to use every reasonable endeavor to carry out the terms and the respective obligations of this Agreement but should the
action of their parties or economic conditions outside the control of either party, create a situation in which the effect of any provisions hereof is severely inequitable, then the parties agree to
negotiate in good faith for such revision of this Agreement as may be reasonable to reach an equitable resolution, including early termination. 

11

 

        Either
party desiring to negotiate for revision in accordance with this Section shall give the other party a statement in writing setting forth the circumstances of the hardship suffered
from, with a request for a meeting of representatives at the time and place convenient to such party in a period between thirty (30) and sixty (60) days following the request. The other
party shall not withhold its agreement unreasonably. 

        Section 12.2  All
notices given or requests made under this Agreement shall be in writing and shall be delivered or mailed by certified or registered mail with a
return receipt requested or by a reputable express delivery service to the party for which it is intended at its address as set forth below, or at such other addresses as the addressee may have
designated to the other party in writing. Any notice shall be deemed given only upon actual delivery thereof at the proper address. 

	All notices to MedImmune Oncology shall be addressed to:
	

 	
 	

MedImmune Oncology, Inc.
	 	 	c/o MedImmune, Inc.
	 	 	660 Research Drive
	 	 	Frederick, MD 21703
	

 	
 	

Attn: Senior Director, Materials Management and Contract manufacturing with a copy to the office of the General Counsel, Business Development Dept. located at
	

 	
 	

MedImmune, Inc.
	 	 	35 West Watkins Mill Road
	 	 	Gaithersburg, MD 20878
	

All notices to PPG shall be addressed to:
	

 	
 	

Attn: Business Manager, PPG-Sipsy US Operations with a copy to the office of the General Counsel
	 	 	PPG Sispy, A Unit of PPG-Industries, Inc.
	 	 	One PPG Place, 36th Floor
	 	 	Pittsburgh, PA 15272 USA

        Section 12.3  The
parties hereto shall use their best efforts to settle amicably any controversy arising out of this Agreement. Should no amicable settlements be
reached, any dispute arising in connection with this Agreement shall be finally settled under the Rules of Conciliation and Arbitration of the International Chamber of Commerce by one or more
arbitrators appointed in accordance with the said Rules. The place of arbitration shall be New York, New York. Language of arbitration shall be the English language. 

        Section 12.4  This
Agreement shall inure to the benefit of and be binding upon the undersigned parties, their respective legal successors and assigns. This Agreement
specifically contemplates that either party shall have the right to assign their rights and duties under this Agreement, subject to prior approval of the other, such approval not to be unreasonably
withheld. In the event that this Agreement is assigned to a third party, the assignor shall remain responsible for the performance of the obligations by its assignee herein and the assignor shall
remain severally and jointly liable with the assignee for the failure to perform its obligations provided for herein. 

        Section 12.5  PPG
shall notify MedImmune Oncology promptly after any change of control of PPG. MedImmune Oncology shall have the right to reasonably terminate this
Agreement by notice to PPG within 60 days after receipt of PPG's notice in accordance with the preceding sentence, such termination to take effect 180 days after the change of control.
For purposes of this Agreement a "change in control" shall mean (i) a merger, consolidation or combination in which PPG is not the surviving corporation; (ii) a change in ownership such
that any person or entity becomes the beneficial 

12

 

owner,
directly or indirectly of 50% or more of the combined voting power of PPG's then outstanding voting securities; or (iii) a purchase of the business or assets of PPG necessary to perform
the services contracted for hereunder. 

        Section 12.6  This
Agreement may not be changed, waived, discharged, or terminated orally, but only by an instrument in writing signed by the parties. 

        Section 12.7  The
parties agree that the provision of the Agreement, together with any amendments, schedules and attachments hereto, represent the entire agreement
between them with respect to the subject matter hereof and supersede any other agreements or understandings they may have with respect thereto. 

        Section 12.8  This
Agreement shall be governed by and construed, interpreted, enforced and applied in accordance with the law of the State of New York. 

        Section 12.9  This
Agreement shall be executed in duplicate originals with each party retaining one original for its files. 

        Section 12.10  The
invalidity of one or more provisions of this Agreement shall not affect the validity of the Agreement as a whole, unless the invalid provisions are
of such essential importance to this Agreement that it is to be reasonably assumed that the parties would not have entered into this Agreement without the invalid provisions. 

        Section 12.11  Should
any part of this Agreement be in conflict with any applicable law, all other provisions of this Agreement shall remain in force and the parties
hereto shall mutually and in good faith modify the conflicting provisions so as to maintain essentially the spirit hereof and the original will of the parties. 

        Section 12.12  Nothing
herein contained shall be deemed to create any relationship in the nature of agency, joint venture, partnership or similar relationship between
MedImmune Oncology and PPG. PPG, its agents, employees, and dealer under no circumstances shall be deemed to be agents, or representatives of MedImmune Oncology, nor will any of them have the right to
enter into any contracts or commitments in the name of MedImmune Oncology or otherwise bind or commit MedImmune Oncology. 

        Section 12.13  Affirmative
Action Notice: PPG is hereby notified that PPG and any subcontractors permitted hereunder may be subject to the provisions of 41 CFR
Section 60-1.4, 41 CFR 60-250.4 and 41 CFR Section 60-741.4 with respect to affirmative action program and plan requirements. 

        WITNESS
the signatures on behalf of the parties hereto by their duly authorized representatives making this Agreement effective as of the date first set forth above. 

	MEDIMMUNE ONCOLOGY, INC.	 	PPG INDUSTRIES, INC.
	

By:	

/s/  MELVIN D. BOOTH      
 Melvin D. Booth	
 	

By:	

/s/  THOMAS VON LEHMER      
 Thomas Von Lehmer
	Title:	President	 	Title:	Vice President
	Date:	1/24/01	 	Date:	1/18/01

13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}]]